Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitapivat in regularly transfused adults with pyruvate kinase deficiency
2017-003803-22Phase 3Completed
- Sponsor
- Agios Pharmaceuticals
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of mitapivat in pyruvate kinase deficiency (PKD), sponsored by Agios Pharmaceuticals. Primary endpoint: Reduction in transfusion burden responder rate. Started Dec 2017; status: completed.
02
Drugs
mitapivat
03
Conditions
pyruvate kinase deficiency (PKD)
Beyond the preview
Go deeper on 2017-003803-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003803-22.